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Current methods of kidney function monitoring, based on plasma creatinine concentration, suffer from poor 
accuracy, lack of sensitivity, and potentially long delay times (24-72 hrs) before detecting acute kidney injury.  A 
kidney function monitor is being developed by MediBeacon, based on transdermally measured fluorescence 
clearance of the novel fluorescent tracer agent, MB-102.  After vascular injection, the agent equilibrates into the 
extracellular spaces of the body and is cleared exclusively by the 
kidneys, without being metabolized.  Plasma pharmacokinetic (PK) 
analysis of MB-102 compared to the known GFR agent, iohexol, 
across subjects with a wide range of chronic kidney disease states, 
has demonstrated the close equivalence (R2=0.99) of the GFR 
derived by the two methods. Transdermal monitoring is 
accomplished using blue (peak ~450 nm) LED excitation to 
induce green (peak ~560 nm) fluorescence of MB-102.  In a pilot 
study, the full day fluorescent decay kinetics of MB-102 were 
shown to be directly related to body-size normalized GFR (tGFR).  
Achieving accurate GFR assessment from shorter time segments is 
a primary goal, in order to provide near real-time monitoring of 
kidney function, for example in hospital intensive care units (ICU).  
The primary interferents to the tGFR measurement are hemoglobin, 
melanin, and tissue autofluorescence.  The focus of the talk will be 
on the development of several generations of instruments designed 
to address these challenges, and their performance during clinical 
studies to date.  Business and regulatory challenges faced along 
the path toward commercialization of this combination device and 





Figure 1 – MediBeacon Transdermal 
GFR Monitor and Agent 
